Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2022 | editorial

ESMO 2021

verfasst von: Univ.-Prof. Dr. Rupert Bartsch

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Auszug

While still being held in a—largely—virtual format, the 2021 Congress of the European Society for Medical Oncology (ESMO) was a fascinating meeting and clinically relevant results have been reported in many areas of oncology. With regards to its scientific significance, it appears that the ESMO Congress today is on par with the American Society of Clinical Oncology (ASCO) Annual Meeting and therefore, this issue of MEMO provides a series of articles focusing on relevant results presented at the virtual 2021 ESMO congress in the fields of breast cancer, lung cancer, gastrointestinal and genitourinary cancers. …
Nächster Artikel New targeted therapies/small molecules in oncology and hematology
Literatur
1.
2.
3.
4.
Metadaten
Titel
ESMO 2021
verfasst von
Univ.-Prof. Dr. Rupert Bartsch
Publikationsdatum
01.06.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00807-8

Weitere Artikel der Ausgabe 2/2022

COVID-19 crisis and cancer

  • editorial

Renal cell carcinoma—presentation highlights from the ESMO Congress 2021

  • short review

Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer

  • Open Access
  • short review

Antibody–drug conjugates—the magic bullet?

  • Open Access
  • short review

Agony of choice—selecting chronic lymphocytic leukemia treatment in 2022

  • Open Access
  • short review

Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report

  • case report